329 related articles for article (PubMed ID: 24990105)
1. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
7. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Yuan Y; Iloeje U; Li H; Hay J; Yao GB
Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Toy M; Hutton DW; So SK
PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
10. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
11. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Buti M; Brosa M; Casado MA; Rueda M; Esteban R
J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
[TBL] [Abstract][Full Text] [Related]
12. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
13. Disease burden of chronic hepatitis B among immigrants in Canada.
Wong WW; Woo G; Heathcote EJ; Krahn M
Can J Gastroenterol; 2013 Mar; 27(3):137-47. PubMed ID: 23516678
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
[TBL] [Abstract][Full Text] [Related]
15. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective.
Veldhuijzen IK; Toy M; Hahné SJ; De Wit GA; Schalm SW; de Man RA; Richardus JH
Gastroenterology; 2010 Feb; 138(2):522-30. PubMed ID: 19879275
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
17. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
20. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
